Skip to main content
. 2016 Mar;13(1):87–100. doi: 10.28092/j.issn.2095-3941.2016.0010

Figure2.

Figure2

Major oncogenic mechanisms in LSCC and therapeutic opportunities. Dysregulated pathways common to LSCCs with targeted therapies in clinical trials for HNSCCs are shown76. WNT974 targets PORCN thereby blocking Wnt ligand secretion from neighboring cells.